A phase I study of the vascular endothelial growth factor inhibitor Vatalanib in combination with Pemetrexed disodium in patients with advanced solid tumors

@article{Wang2018API,
  title={A phase I study of the vascular endothelial growth factor inhibitor Vatalanib in combination with Pemetrexed disodium in patients with advanced solid tumors},
  author={Fen Wang and Julian Vargas Molina and Daniel V. Satele and Jun Yin and Vun-Sin Lim and Austin P. Huffman},
  journal={Investigational New Drugs},
  year={2018},
  pages={1-8}
}
Introduction Vatalanib is an oral receptor tyrosine kinase inhibitor that blocks all known VEGF, PDGF, and c-Kit receptors. This phase I study evaluated the safety, tolerability, and biologic activity of the combination of vatalanib with pemetrexed disodium in patients with advanced solid tumors. Methods Patients were administered escalating twice daily doses of vatalanib in combination with pemetrexed disodium in 21-day cycles. A dose expansion cohort was enrolled to further define the maximum… CONTINUE READING
BETA

References

Publications referenced by this paper.
SHOWING 1-10 OF 60 REFERENCES

Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2009
VIEW 8 EXCERPTS
HIGHLY INFLUENTIAL

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2004
VIEW 9 EXCERPTS
HIGHLY INFLUENTIAL

Similar Papers

Loading similar papers…